Clinical Trial Update: Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study evaluating MIJ821 for treatment-resistant depression has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• MIJ821

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Depressive Disorder, Treatment-Resistant | Phase 2 | Status: COMPLETED | Results posted: 2021-05-19